{"id":"ct-p51","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-15","effect":"Bleeding/hemorrhage"},{"rate":"5-10","effect":"Thromboembolic events"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"}]},"_chembl":{"chemblId":"CHEMBL4297274","moleculeType":"Small molecule","molecularWeight":"533.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P51 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling protein that promotes the formation of new blood vessels. By blocking VEGF, the drug prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a bevacizumab biosimilar developed by Celltrion, it is designed to have comparable efficacy and safety to the reference biologic.","oneSentence":"CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:00.307Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06939595","phase":"PHASE3","title":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-01-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P51","genericName":"CT-P51","companyName":"Celltrion","companyId":"celltrion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}